{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:57:41Z","timestamp":1780959461073,"version":"3.54.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"23","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R37CA230630"],"award-info":[{"award-number":["R37CA230630"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA188563"],"award-info":[{"award-number":["K08CA188563"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["133649-RSG-19-019-01-CSM"],"award-info":[{"award-number":["133649-RSG-19-019-01-CSM"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The intrinsic ability of cancer cells to evade death underpins tumorigenesis, progression, metastasis, and the survival of drug-tolerant persister (DTP) cells. Herein, we discovered that the small GTPase ARF6 plays a central role in tumor survival by fortifying RAF oncoprotein levels. ARF6 activation was sufficient to increase BRAF\n                    <jats:sup>V600E<\/jats:sup>\n                    , ARAF, and CRAF proteins through a post-transcriptional mechanism, while sustained inhibition of ARF6 eventually led to decay. In a genetically engineered model of aggressive melanoma, tumor-specific\n                    <jats:italic>Arf6<\/jats:italic>\n                    deletion attenuated BRAF\n                    <jats:sup>V600E<\/jats:sup>\n                    protein expression and MAPK signaling and prevented rapid tumor progression. In human melanoma cells, pharmacologic inhibitors of BRAF\n                    <jats:sup>V600E<\/jats:sup>\n                    uniformly induced swift activation of ARF6, driving a positive feedback loop that restored MAPK-driven anti-apoptotic signaling and supported drug-tolerant survival and growth. Furthermore, in patient-derived melanoma xenografts with innate or clinically acquired resistance to MAPK inhibitors, ARF6 silencing alone significantly suppressed tumor growth in vivo. When combined with BRAF and MEK targeted therapy in vitro, inhibition of ARF6 markedly reduced survival and drug-tolerant growth. Collectively, these findings reveal a previously unknown mechanism of maintaining BRAF\n                    <jats:sup>V600E<\/jats:sup>\n                    protein expression that preserves the MAPK pathway during targeted therapy. This ARF6-dependent mechanism may be exploited in BRAF\n                    <jats:sup>V600E<\/jats:sup>\n                    driven cancers as a therapeutic vulnerability.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03805-w","type":"journal-article","created":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:59:41Z","timestamp":1777373981000},"page":"2286-2298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid activation of ARF6 after RAF inhibition augments BRAFV600E and promotes therapy resistance"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4424-8502","authenticated-orcid":false,"given":"Junhua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinshen","family":"Wee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise. K.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deja M.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prachi","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0626-8662","authenticated-orcid":false,"given":"Joshua K. H.","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4037-9366","authenticated-orcid":false,"given":"Emily C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-5603","authenticated-orcid":false,"given":"Eric A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YN Vashisht","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0977-0912","authenticated-orcid":false,"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2812-1042","authenticated-orcid":false,"given":"Martin","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6411-6032","authenticated-orcid":false,"given":"Sheri L.","family":"Holmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6559-0553","authenticated-orcid":false,"given":"Robert L.","family":"Judson-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger K.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-1403","authenticated-orcid":false,"given":"Allie H.","family":"Grossmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"3805_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"3805_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","volume":"20","author":"Y Pu","year":"2023","unstructured":"Pu Y, Li L, Peng H, Liu L, Heymann D, Robert C, et al. Drug-tolerant persister cells in cancer: the cutting edges and future directions. Nat Rev Clin Oncol. 2023;20:799\u2013813.","journal-title":"Nat Rev Clin Oncol"},{"key":"3805_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","volume":"9","author":"J He","year":"2024","unstructured":"He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X. Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies. Signal Transduct Target Ther. 2024;9:209.","journal-title":"Signal Transduct Target Ther"},{"key":"3805_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02323-9","volume":"24","author":"S Liu","year":"2025","unstructured":"Liu S, Jiang A, Tang F, Duan M, Li B. Drug-induced tolerant persisters in tumor: mechanism, vulnerability and perspective implication for clinical treatment. Mol Cancer. 2025;24:150.","journal-title":"Mol Cancer"},{"key":"3805_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3805_CR6","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas N.","year":"2015","unstructured":"Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. Cell. 2015;161:1681\u201396.","journal-title":"Cell"},{"key":"3805_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","volume":"21","author":"AJ Hanrahan","year":"2024","unstructured":"Hanrahan AJ, Chen Z, Rosen N, Solit DB. BRAF - a tumour-agnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol. 2024;21:224\u201347.","journal-title":"Nat Rev Clin Oncol"},{"key":"3805_CR8","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-18-3026","volume":"79","author":"JH Yoo","year":"2019","unstructured":"Yoo JH, Brady SW, Acosta-Alvarez L, Rogers A, Peng J, Sorensen LK, et al. The Small GTPase ARF6 activates PI3K in melanoma to induce a prometastatic state. Cancer Res. 2019;79:2892\u2013908.","journal-title":"Cancer Res"},{"key":"3805_CR9","doi-asserted-by":"publisher","first-page":"9671","DOI":"10.1073\/pnas.0403531101","volume":"101","author":"SE Tague","year":"2004","unstructured":"Tague SE, Muralidharan V, D\u2019Souza-Schorey C. ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK\/ERK signaling pathway. Proc Natl Acad Sci USA (Res Support, U S Gov\u2019t, Non-P H S). 2004;101:9671\u20136.","journal-title":"Proc Natl Acad Sci USA (Res Support, U S Gov\u2019t, Non-P H S)"},{"key":"3805_CR10","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/s41388-023-02792-6","volume":"42","author":"JR Richards","year":"2023","unstructured":"Richards JR, Shin D, Pryor R, Sorensen LK, Sun Z, So WM, et al. Activation of NFAT by HGF and IGF-1 via ARF6 and its effector ASAP1 promotes uveal melanoma metastasis. Oncogene. 2023;42:2629\u201340.","journal-title":"Oncogene"},{"key":"3805_CR11","doi-asserted-by":"publisher","first-page":"ra14","DOI":"10.1126\/scisignal.2003398","volume":"6","author":"AH Grossmann","year":"2013","unstructured":"Grossmann AH, Yoo JH, Clancy J, Sorensen LK, Sedgwick A, Tong Z, et al. The small GTPase ARF6 stimulates beta-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis. Sci Signal. 2013;6:ra14.","journal-title":"Sci Signal"},{"key":"3805_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50881-1","volume":"15","author":"Y Wee","year":"2024","unstructured":"Wee Y, Wang J, Wilson EC, Rich CP, Rogers A, Tong Z, et al. Tumour-intrinsic endomembrane trafficking by ARF6 shapes an immunosuppressive microenvironment that drives melanomagenesis and response to checkpoint blockade therapy. Nat Commun. 2024;15:6613.","journal-title":"Nat Commun"},{"key":"3805_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ccell.2016.04.015","volume":"29","author":"JH Yoo","year":"2016","unstructured":"Yoo JH, Shi DS, Grossmann AH, Sorensen LK, Tong Z, Mleynek TM, et al. ARF6 is an actionable node that orchestrates oncogenic GNAQ signaling in uveal melanoma. Cancer Cell. 2016;29:889\u2013904.","journal-title":"Cancer Cell"},{"key":"3805_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500\u20134.","journal-title":"Nature"},{"key":"3805_CR15","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1172\/JCI70156","volume":"124","author":"JN Anastas","year":"2014","unstructured":"Anastas JN, Kulikauskas RM, Tamir T, Rizos H, Long GV, von Euw EM, et al. WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors. J Clin Invest. 2014;124:2877\u201390.","journal-title":"J Clin Invest"},{"key":"3805_CR16","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1158\/2159-8290.CD-13-0005","volume":"3","author":"MP O\u2019Connell","year":"2013","unstructured":"O\u2019Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013;3:1378\u201393.","journal-title":"Cancer Discov"},{"key":"3805_CR17","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1158\/1078-0432.CCR-17-0201","volume":"23","author":"R Behera","year":"2017","unstructured":"Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH 3rd, et al. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of Klotho. Clin Cancer Res. 2017;23:3181\u201390.","journal-title":"Clin Cancer Res"},{"key":"3805_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrm1910","volume":"7","author":"C D\u2019Souza-Schorey","year":"2006","unstructured":"D\u2019Souza-Schorey C, Chavrier P. ARF proteins: roles in membrane traffic and beyond. Nat Rev Mol Cell Biol (Rev). 2006;7:347\u201358.","journal-title":"Nat Rev Mol Cell Biol (Rev)"},{"key":"3805_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4161\/sgtp.19301","volume":"3","author":"R Brooks","year":"2012","unstructured":"Brooks R, Williamson R, Bass M. Syndecan-4 independently regulates multiple small GTPases to promote fibroblast migration during wound healing. Small GTPases. 2012;3:73\u20139.","journal-title":"Small GTPases"},{"key":"3805_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09633-z","volume":"7","author":"MT Tsai","year":"2017","unstructured":"Tsai MT, Katagiri N, Ohbayashi N, Iwasaki K, Ohkohchi N, Ding ST, et al. Regulation of HGF-induced hepatocyte proliferation by the small GTPase Arf6 through the PIP2-producing enzyme PIP5K1A. Sci Rep. 2017;7:9438.","journal-title":"Sci Rep"},{"key":"3805_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1080\/21541248.2018.1457914","volume":"11","author":"B Nieuwenhuis","year":"2020","unstructured":"Nieuwenhuis B, Eva R. ARF6 and Rab11 as intrinsic regulators of axon regeneration. Small GTPases. 2020;11:392\u2013401.","journal-title":"Small GTPases"},{"key":"3805_CR22","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1074\/jbc.M113.499194","volume":"289","author":"T Van Acker","year":"2014","unstructured":"Van Acker T, Eyckerman S, Vande Walle L, Gerlo S, Goethals M, Lamkanfi M, et al. The small GTPase Arf6 is essential for the Tram\/Trif pathway in TLR4 signaling. J Biol Chem. 2014;289:1364\u201376.","journal-title":"J Biol Chem"},{"key":"3805_CR23","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.3389\/fimmu.2018.03098","volume":"9","author":"S Montealegre","year":"2018","unstructured":"Montealegre S, van Endert PM. Endocytic recycling of MHC class I molecules in non-professional antigen presenting and dendritic cells. Front Immunol. 2018;9:3098.","journal-title":"Front Immunol"},{"key":"3805_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11919","volume":"7","author":"C Marquer","year":"2016","unstructured":"Marquer C, Tian H, Yi J, Bastien J, Dall\u2019Armi C, Yang-Klingler Y, et al. Arf6 controls retromer traffic and intracellular cholesterol distribution via a phosphoinositide-based mechanism. Nat Commun. 2016;7:11919.","journal-title":"Nat Commun"},{"key":"3805_CR25","doi-asserted-by":"publisher","first-page":"e0285253","DOI":"10.1371\/journal.pone.0285253","volume":"18","author":"VR Gogulamudi","year":"2023","unstructured":"Gogulamudi VR, Islam MT, Durrant JR, Adeyemo AO, Trott DW, Hyuhn MH, et al. Heterozygosity for ADP-ribosylation factor 6 suppresses the burden and severity of atherosclerosis. PLoS One. 2023;18:e0285253.","journal-title":"PLoS One"},{"key":"3805_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8925","volume":"6","author":"T Hongu","year":"2015","unstructured":"Hongu T, Funakoshi Y, Fukuhara S, Suzuki T, Sakimoto S, Takakura N, et al. Arf6 regulates tumour angiogenesis and growth through HGF-induced endothelial beta1 integrin recycling. Nat Commun. 2015;6:7925.","journal-title":"Nat Commun"},{"key":"3805_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature11603","volume":"492","author":"W Zhu","year":"2012","unstructured":"Zhu W, London NR, Gibson CC, Davis CT, Tong Z, Sorensen LK, et al. Interleukin receptor activates a MYD88-ARNO-ARF6 cascade to disrupt vascular stability. Nature. 2012;492:252\u20135.","journal-title":"Nature"},{"key":"3805_CR28","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1038\/ncb1976","volume":"11","author":"CA Jones","year":"2009","unstructured":"Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nat Cell Biol. 2009;11:1325\u201331.","journal-title":"Nat Cell Biol"},{"key":"3805_CR29","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1172\/JCI91770","volume":"127","author":"W Zhu","year":"2017","unstructured":"Zhu W, Shi DS, Winter JM, Rich BE, Tong Z, Sorensen LK. et al. Small GTPase ARF6 controls VEGFR2 trafficking AND signaling in diabetic retinopathy. J Clin Invest. 2017;127:4569\u201382.","journal-title":"J Clin Invest"},{"key":"3805_CR30","doi-asserted-by":"publisher","first-page":"6045","DOI":"10.4049\/jimmunol.1400309","volume":"192","author":"CT Davis","year":"2014","unstructured":"Davis CT, Zhu W, Gibson CC, Bowman-Kirigin JA, Sorensen L, Ling J, et al. ARF6 inhibition stabilizes the vasculature and enhances survival during endotoxic shock. J Immunol. 2014;192:6045\u201352.","journal-title":"J Immunol"},{"key":"3805_CR31","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1073\/pnas.0702136104","volume":"104","author":"Q Zhang","year":"2007","unstructured":"Zhang Q, Major MB, Takanashi S, Camp ND, Nishiya N, Peters EC, et al. Small-molecule synergist of the Wnt\/beta-catenin signaling pathway. Proc Natl Acad Sci USA 2007;104:7444\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3805_CR32","doi-asserted-by":"publisher","first-page":"10686","DOI":"10.1158\/0008-5472.CAN-05-2632","volume":"65","author":"S da Rocha Dias","year":"2005","unstructured":"da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2005;65:10686\u201391.","journal-title":"Cancer Res"},{"key":"3805_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1073\/pnas.0609973103","volume":"103","author":"OM Grbovic","year":"2006","unstructured":"Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006;103:57\u201362.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3805_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1083\/jcb.140.3.603","volume":"140","author":"C D\u2019Souza-Schorey","year":"1998","unstructured":"D\u2019Souza-Schorey C, van Donselaar E, Hsu VW, Yang C, Stahl PD, Peters PJ. ARF6 targets recycling vesicles to the plasma membrane: insights from an ultrastructural investigation. J Cell Biol. 1998;140:603\u201316.","journal-title":"J Cell Biol"},{"key":"3805_CR35","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1083\/jcb.200305029","volume":"163","author":"M Prigent","year":"2003","unstructured":"Prigent M, Dubois T, Raposo G, Derrien V, Tenza D, Rosse C, et al. ARF6 controls post-endocytic recycling through its downstream exocyst complex effector. J Cell Biol. 2003;163:1111\u201321.","journal-title":"J Cell Biol"},{"key":"3805_CR36","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/jcb.23362","volume":"113","author":"AV Knizhnik","year":"2012","unstructured":"Knizhnik AV, Kovaleva OV, Komelkov AV, Trukhanova LS, Rybko VA, Zborovskaya IB, et al. Arf6 promotes cell proliferation via the PLD-mTORC1 and p38MAPK pathways. J Cell Biochem. 2012;113:360\u201371.","journal-title":"J Cell Biochem"},{"key":"3805_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70872","volume":"14","author":"H Xu","year":"2025","unstructured":"Xu H, Chen D, Lu J, Zhong L, Wang L, Ge J. ARF6 promotes AML progression via activation of PI3K\/AKT\/mTOR signaling. Cancer Med. 2025;14:e70872.","journal-title":"Cancer Med"},{"key":"3805_CR38","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nature05415","volume":"444","author":"M Hafner","year":"2006","unstructured":"Hafner M, Schmitz A, Grune I, Srivatsan SG, Paul B, Kolanus W, et al. Inhibition of cytohesins by SecinH3 leads to hepatic insulin resistance. Nature. 2006;444:941\u20134.","journal-title":"Nature"},{"key":"3805_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.102992","volume":"299","author":"EM Rosenberg Jr","year":"2023","unstructured":"Rosenberg EM Jr, Jian X, Soubias O, Yoon HY, Yadav MP, Hammoudeh S, et al. The small molecule inhibitor NAV-2729 has a complex target profile including multiple ADP-ribosylation factor regulatory proteins. J Biol Chem. 2023;299:102992.","journal-title":"J Biol Chem"},{"key":"3805_CR40","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1158\/1535-7163.MCT-16-0017","volume":"15","author":"H Kawakami","year":"2016","unstructured":"Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and cobimetinib in colorectal cancer. Mol Cancer Ther. 2016;15:3015\u201327.","journal-title":"Mol Cancer Ther"},{"key":"3805_CR41","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/ncb1676","volume":"10","author":"JY Yang","year":"2008","unstructured":"Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, et al. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol. 2008;10:138\u201348.","journal-title":"Nat Cell Biol"},{"key":"3805_CR42","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"6","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW, et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Target Ther. 2021;6:425.","journal-title":"Signal Transduct Target Ther"},{"key":"3805_CR43","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1158\/0008-5472.CAN-19-2924","volume":"80","author":"I Bok","year":"2020","unstructured":"Bok I, Vera O, Xu X, Jasani N, Nakamura K, Reff J, et al. A versatile ES cell-based melanoma mouse modeling platform. Cancer Res. 2020;80:912\u201321.","journal-title":"Cancer Res"},{"key":"3805_CR44","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/0008-5472.CAN-23-1730","volume":"84","author":"X Xu","year":"2024","unstructured":"Xu X, Bok I, Jasani N, Wang K, Chadourne M, Mecozzi N, et al. PTEN lipid phosphatase activity suppresses melanoma formation by opposing an AKT\/mTOR\/FRA1 Signaling Axis. Cancer Res. 2024;84:388\u2013404.","journal-title":"Cancer Res"},{"key":"3805_CR45","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.celrep.2015.09.057","volume":"13","author":"JH Cho","year":"2015","unstructured":"Cho JH, Robinson JP, Arave RA, Burnett WJ, Kircher DA, Chen G, et al. AKT1 activation promotes development of melanoma metastases. Cell Rep. 2015;13:898\u2013905.","journal-title":"Cell Rep"},{"key":"3805_CR46","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1158\/2159-8290.CD-24-0024","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger R, McKean MA, Haq R, Beck JT, Taylor MH, Cohen JE, et al. A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation. Cancer Discov. 2024;14:1599\u2013611.","journal-title":"Cancer Discov"},{"key":"3805_CR47","unstructured":"Melanoma: Cutaneous. NCCN Clinical Practice Guidelines in Oncology, V2.2025 edn. National Comprehensive Cancer Network, 2025."},{"key":"3805_CR48","doi-asserted-by":"publisher","first-page":"D1210","DOI":"10.1093\/nar\/gkad986","volume":"52","author":"Sondka","year":"2024","unstructured":"Sondka, Dhir Z, Carvalho-Silva NB, Jupe D, Madhumita S, McLaren K, et al. COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res. 2024;52:D1210\u20137.","journal-title":"Nucleic Acids Res"},{"key":"3805_CR49","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s13046-024-03234-1","volume":"43","author":"EA Smith","year":"2024","unstructured":"Smith EA, Belote RL, Cruz NM, Moustafa TE, Becker CA, Jiang A, et al. Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment. J Exp Clin Cancer Res. 2024;43:317.","journal-title":"J Exp Clin Cancer Res"},{"key":"3805_CR50","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ccell.2025.02.001","volume":"43","author":"S Lubrano","year":"2025","unstructured":"Lubrano S, Cervantes-Villagrana RD, Faraji F, Ramirez S, Sato K, Adame-Garcia SR, et al. FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer Cell. 2025;43:428\u201345.e426.","journal-title":"Cancer Cell"},{"key":"3805_CR51","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","volume":"22","author":"P Lito","year":"2012","unstructured":"Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell. 2012;22:668\u201382.","journal-title":"Cancer Cell"},{"key":"3805_CR52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nchembio.1212","volume":"9","author":"S Polier","year":"2013","unstructured":"Polier S, Samant RS, Clarke PA, Workman P, Prodromou C, Pearl LH. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat Chem Biol. 2013;9:307\u201312.","journal-title":"Nat Chem Biol"},{"key":"3805_CR53","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41392-024-01749-9","volume":"9","author":"X Jia","year":"2024","unstructured":"Jia X, He X, Huang C, Li J, Dong Z, Liu K. Protein translation: biological processes and therapeutic strategies for human diseases. Signal Transduct Target Ther. 2024;9:44.","journal-title":"Signal Transduct Target Ther"},{"key":"3805_CR54","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1016\/j.molcel.2023.05.019","volume":"83","author":"NM Livingston","year":"2023","unstructured":"Livingston NM, Kwon J, Valera O, Saba JA, Sinha NK, Reddy P, et al. Bursting translation on single mRNAs in live cells. Mol Cell. 2023;83:2276\u201389.e2211.","journal-title":"Mol Cell"},{"key":"3805_CR55","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/0008-5472.CAN-24-2220","volume":"85","author":"S Gadal","year":"2025","unstructured":"Gadal S, Boyer JA, Roy SF, Outmezguine NA, Sharma M, Li H. et al. Tumorigenesis driven by BRAFV600E requires secondary mutations that overcome it\u2019s feedback inhibition of RAC1 AND migration. Cancer Res. 2025;85:1611\u201327.","journal-title":"Cancer Res"},{"key":"3805_CR56","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ccell.2019.05.015","volume":"36","author":"DA Lionarons","year":"2019","unstructured":"Lionarons DA, Hancock DC, Rana S, East P, Moore C, Murillo MM, et al. RAC1(P29S) induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance. Cancer Cell. 2019;36:68\u201383.e69.","journal-title":"Cancer Cell"},{"key":"3805_CR57","doi-asserted-by":"publisher","first-page":"4845","DOI":"10.1158\/0008-5472.CAN-14-1232-T","volume":"74","author":"IR Watson","year":"2014","unstructured":"Watson IR, Li L, Cabeceiras PK, Mahdavi M, Gutschner T, Genovese G, et al. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF. Cancer Res. 2014;74:4845\u201352.","journal-title":"Cancer Res"},{"key":"3805_CR58","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1038\/s41388-025-03603-w","volume":"44","author":"JD Riordan","year":"2025","unstructured":"Riordan JD, Nathanson TA, Varzavand A, Hawkins AA, Peplinski RM, Hannan EC. et al. A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition. Oncogene. 2025;44:4520\u201332.","journal-title":"Oncogene"},{"key":"3805_CR59","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.devcel.2014.10.025","volume":"31","author":"J Yue","year":"2014","unstructured":"Yue J, Xie M, Gou X, Lee P, Schneider MD, Wu X. Microtubules regulate focal adhesion dynamics through MAP4K4. Dev Cell. 2014;31:572\u201385.","journal-title":"Dev Cell"},{"key":"3805_CR60","doi-asserted-by":"publisher","first-page":"eaav5938","DOI":"10.1126\/scisignal.aav5938","volume":"12","author":"M Ghosh","year":"2019","unstructured":"Ghosh M, Lo R, Ivic I, Aguilera B, Qendro V, Devarakonda C. CD13 tethers the IQGAP1-ARF6-EFA6 complex to the plasma membrane to promote ARF6 activation beta1 integrin recycling AND cell migration. Sci Signal. 2019;12:eaav5938","journal-title":"Sci Signal"},{"key":"3805_CR61","doi-asserted-by":"publisher","first-page":"e92444","DOI":"10.1371\/journal.pone.0092444","volume":"9","author":"C Guzman","year":"2014","unstructured":"Guzman C, Bagga M, Kaur A, Westermarck J, Abankwa D. ColonyArea: an ImageJ plugin to automatically quantify colony formation in clonogenic assays. PLoS One. 2014;9:e92444.","journal-title":"PLoS One"},{"key":"3805_CR62","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1158\/2159-8290.CD-15-0196","volume":"5","author":"AS McNeal","year":"2015","unstructured":"McNeal AS, Liu K, Nakhate V, Natale CA, Duperret EK, Capell BC, et al. CDKN2B loss promotes progression from benign melanocytic nevus to melanoma. Cancer Discov. 2015;5:1072\u201385.","journal-title":"Cancer Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03805-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03805-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03805-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:02:46Z","timestamp":1780956166000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03805-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":62,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2026,6,30]]}},"alternative-id":["3805"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03805-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7133814\/v1","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MAD has been a consultant to Roche\/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics, and he has been the PI of research grants to MD Anderson by Roche\/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research included local researchers throughout the research process, is locally relevant and has been determined in collaboration with local partners. Roles and responsibilities were agreed amongst collaborators ahead of the research and with capacity in mind. This research was not severely restricted or prohibited by local stakeholders. This research was approved by a local ethics review committee and complied with animal welfare regulations, environmental protection, and biorisk-related regulations and the local research setting was sufficient to conduct the research described. No stigmatization, incrimination, discrimination, or personal risk to participants or researchers was involved in this research. The researchers and facilities will not benefit monetarily from sharing biological materials, including if transferred out of the country of origin. Local and regional research relevant to this study have been included in citations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and inclusion statement"}}]}}